Investor Relations
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 13, 2021Company CEO and CFO will also be conducting a presentation that will be available on-demand
-
Sep 8, 2021Peer-reviewed results describe the Company's test being used to confirm the presence of the virus on community waste, including mutated strains
-
Aug 12, 2021Solid quarterly results highlighted by revenue of $27.4 million, pre-tax income of $11.9 million and diluted EPS of $0.33
-
May 13, 2021Strong quarterly results highlighted by revenue of $20.0 million, pre-tax income of $9.9 million and diluted EPS of $0.26
-
Apr 28, 2021Times of India article highlights CoSara's tireless efforts to increase manufacturing of COVID-19 tests in response to deadly wave of infections
-
Apr 20, 2021Paper published in the Journal of Medical Microbiology utilizes Company's test in rapidly deployable mobile molecular diagnostics
-
Mar 25, 2021Record quarterly results highlighted by revenue of $27.1 million and pre-tax income of $15.8 million
-
Mar 2, 2021Proprietary platform includes countertop device being developed for Co-Diagnostics by world experts in rapid PCR
-
Feb 25, 2021Clinical Reference Laboratory's FDA-authorized saliva-based PCR test uses technology developed by Co-Diagnostics to detect SARS-CoV-2
-
Feb 23, 2021Company also elevates in-house Senior VP of Biochemistry to Chief Scientific Officer
-
Feb 16, 2021Company believes direct saliva to play a key role in high throughput, point of care, and at home applications
-
Jan 28, 2021The Company's Logix Smart™ SARS-CoV-2 DS (Direct Saliva) test is designed to reduce sample processing time and cost by eliminating the extraction process